[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 646 participants.
Also called NCT01408303
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 646 participants
- Sponsor
- Registry
-
NCT01408303
-
- Other papers using this trial's data
- A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial)
- Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01408303. Randomized; quadruple masking; primary purpose treatment. Start 2011-08 (registry gives no type); primary completion 2012-06 (actual). Results posted on 2014-12-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
- Acronym
- ESPRIT
- Condition
- Hypertriglyceridemia
- Condition
- Cardiovascular Disease
- Intervention (Drug)
- Olive oil, 4g
- Intervention (Drug)
- omega-3-carboxylic acids, 2g
- Intervention (Drug)
- omega-3-carboxylic acids, 4g
- Lead sponsor
- AstraZeneca
- Collaborator
- Omthera Pharmaceuticals, Inc
- Collaborator
- Medpace, Inc.
Record details
- Record id
cardio:ct-nct01408303- Content hash
701c305afb61578f57d4170f026f9901a0f51a6694e80fa463d8b7ef41c9258d